After demonstrating that cyclin D1-CDK4 activity is important for response to bortezomib in MCL cells (Fig. 1), we next asked if this also holds true for the more effective combination of bortezomib with orlistat. The gene discussed is CCND1; the disease is mantle cell lymphoma.